For Healthcare Professionals

A citrate supplement
built for adherence

Review the evidence behind KSPtabs, explore practical considerations for patient use, and request complimentary samples and educational materials for your practice.

15 mEq potassium citrate per tablet Effervescent OTC formulation Three flavor options
View Clinical Evidence Request Samples
Urologist-developed Trusted expertise.
Clinically studied See the science.
Made for real life Easy to drink. Easy to keep up.
3 delicious flavors Designed for daily use.
Doctor speaking with patient about kidney stone prevention

KSPtabs: Key Findings

Clinical evidence and practice-based findings.

Review the study populations, methods, outcomes, and limitations associated with the available KSPtabs data.

Peer-reviewed clinical study

Healthy adults, n=10 Primary evidence

+87%
urinary citrate
597 → 797 mg/day · p=0.037
+6%
urine pH
6.46 → 6.86 · p=0.037
Study context: Prospective crossover study in healthy adults (Journal of Urology, 2021). Small sample size; participants were not kidney stone formers. Findings may not directly generalize to stone-forming patients.

Practice-based observational findings

Stone-forming patients, n=35

+50%
urine volume
Increase from baseline
-74%
uric acid supersaturation (SS uric acid)
Decrease from baseline
Data context: Real-world outcomes from 35 active stone-forming patients in clinical urology care. Observational pre/post data; not peer-reviewed. Individual results may vary.

Formulation and access

Product specifications

15 mEq
potassium citrate per tablet
Effervescent OTC formulation
$1.35
as little as, per day
No prescription required
Access context: KSPtabs is an OTC effervescent dietary supplement available without a prescription. Estimated cost based on 2–3 tablets daily; may vary by purchase option. Available in three flavors.

Professional Resources

Everything you need in one place

Medical researcher reviewing KSPtabs clinical study data in laboratory

Clinical Research

The Evidence Behind KSPtabs

Peer-reviewed crossover study data, AUA 2026 guideline alignment, PUSH trial results, and a full methods + limitations review. Everything you need to evaluate KSPtabs with confidence.

  • Urinary citrate & pH outcomes
  • AUA Statement 36 — effervescent OTC citrate
  • Comparison vs. water & prescription Rx
Explore the Evidence →
Physician consulting with patient on KSPtabs potassium citrate for kidney stone prevention

Clinical Application

Using KSPtabs in Practice

Who to recommend it to, how to frame it in the visit, 24-hour urine targets, and counseling language that improves adherence. Practical guidance for urology, nephrology, and primary care.

  • Patient selection by stone type & labs
  • Dosing guidance & citrate targets
  • Conversation starters for your patients
See the Clinical Guide →
KSPtabs effervescent potassium citrate clinical sample pack for healthcare providers

Clinical Samples

Request Clinical Samples

We ship samples — all 3 flavors — directly to your practice. Try them yourself and share with your patients. Also available: rack cards and patient handouts.

  • All 3 flavors: Key Lime, Sunrise Citrus, Very Berry
  • Patient education materials included
  • Ships to your practice address
Request Samples →
For Medical Professionals

Interested in evaluating KSPtabs with your patients?

Request samples and provider information for your practice.

Request Clinical Samples
Easy to integrate Simple dosing. Easy for patients to use.
Patient-centered Designed to support adherence and routine.
Backed by science Clinical evidence and real-world outcomes.

Important information

This page is intended for licensed healthcare providers. It is not intended as direct-to-consumer medical advice. All sample requests are subject to verification of professional licensure.
KSPtabs is a dietary supplement. These statements have not been evaluated by the Food and Drug Administration. KSPtabs is not intended to diagnose, treat, cure, or prevent any disease.
Data referenced reflects specific study designs with limited sample sizes. The peer-reviewed crossover study enrolled healthy adults (n=10), not stone-forming patients. Practice-based findings are uncontrolled and not peer-reviewed. Results may not apply to all patients. Clinicians should apply independent judgment in patient care decisions.